Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CP-ICG is a near-infrared (NIR) fluorescent molecular probe used as a non-targeting control in preclinical imaging research. It consists of a control peptide (CP) conjugated to the fluorophore Indocyanine Green (ICG). In studies of ovarian cancer metastases, CP-ICG serves as a comparator to evaluate the specific targeting efficiency of ligand-directed probes, such as the Trop2-targeted TP-ICG. By providing a measure of non-specific probe accumulation and background signal, CP-ICG allows researchers to quantify the signal-to-background ratio (SBR) improvements achieved by targeted imaging agents in the NIR-II window. It is primarily used in mouse models to establish baseline fluorescence levels during real-time intraoperative tumor boundary assessment and metastatic foci visualization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CP-ICG.